Purchase Order 75N95024P00163
Award Date
3/1/24
Potential Completion Date
3/14/24
Potential Value
$25K
Funding Federal Agency
National Center for Advancing Translational Sciences
Contracting Federal Agency
National Institute on Drug Abuse
Awardee
Promega Corporation
Ultimate Awardee
Not listed
PSC Category
6505 - Drugs And Biologicals
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Madison, WI 53711, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price purchase order awarded by the Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences to Promega Corporation, a global life sciences company, for the supply of CELLTITER-GLO(R) ONE SOLUTION ASSAY, 500ML. The potential value of the contract is $13,292.50 and the completion date is September 15, 2023. Promega Corporation is a manufacturer of goods and a for-profit organization that has previously...
The Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences awarded a $24,294.20 firm fixed price purchase order to Promega Corporation for CASPASE-GLO(R) 3/7 ASSAY, 100ML. The contract has a completion date of September 8, 2023 and was awarded on August 18, 2023. This order is not associated with a set-aside program. Promega Corporation is a global life sciences company that provides various biological research and diagnostic...
This is a firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to Promega Corporation for $132,961.50. The order is for Promega's cytochrome P450 screening assay systems to support the Tox21 drug screening program. The assay kits measure the activity of various CYP enzymes, which are critical for evaluating drug metabolism and toxicity. This award was sole-sourced to Promega as the sole...
This contract was awarded by the National Institutes of Health (NIH) National Institute on Drug Abuse to Promega Corporation, a for-profit manufacturer of laboratory equipment, reagents, and consumables. The $113,836.25 firm fixed-price purchase order is for the delivery of Promega's Caspase-Glo 3/7 Assay and CellTiter-Glo One Solution Assay, which are used in cell-based assays to test the apoptosis detection and cytotoxicity of siRNA libraries. The contract does not utilize a set-aside...
This firm-fixed-price purchase order was awarded to Promega Corporation, a global life sciences company, by the National Center for Advancing Translational Sciences (NCATS) within the Department of Health and Human Services' National Institutes of Health. The $121,492.50 contract is for the procurement of detection assay systems with an August 2021 completion date. Promega has previously been awarded prime and subcontracts by various agencies including the NIH, CDC, DoD, and FBI to provide DNA...
This firm-fixed-price purchase order was awarded by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Promega Corporation, a global life sciences company, to provide P450-Glo screening systems including CYP26A1, CYP26B1, and CYP3A4 assay kits. The $123,592.50 contract supports the Tox21 collaboration between NCATS, the National Toxicology Program, EPA, and FDA, which aims to screen thousands of compounds in vitro to develop better toxicity...
The National Center for Advancing Translational Sciences, a civilian agency within the U.S. Department of Health and Human Services, awarded a Firm Fixed Price Purchase Order contract to Promega Corporation, a for-profit manufacturer of biological research and diagnostic products. The $66,970.35 contract is for the delivery of Promega's proprietary laboratory equipment, reagents, and consumables to support the agency's biomedical research and testing programs. This award is under a $10 million...
This federal contract award, valued at $3,451.95, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to Promega Corporation, a global life sciences company headquartered in Madison, Wisconsin. The award is for the purchase of CellTiter-Glo Luminescent Cell Viability Assay reagents, which are used for biological research, molecular diagnostics, and forensic analysis. Promega has supplied a range of specialized laboratory...
The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a firm fixed-price purchase order to Promega Corporation for P450-Glo Assay Systems. The $143,461.50 contract is for the supply of 65 units each of CYP3A4, CYP2D6, and CYP1A2 assay kits to support the Toxicology in the 21st Century (Tox21) program's efforts to screen compounds for effects on cytochrome P450 enzyme activities. Promega is a global life sciences...
The National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), awarded a $55,800 firm-fixed-price purchase order contract to Promega Corporation for the supply of P450-Glo CYP26A1 and CYP26B1 Screening Systems. This non-competitive contract, awarded without set-aside, will provide NCATS with specialized laboratory equipment and reagents to support its biomedical research and testing programs. Promega, a global life sciences company, is a...